131 related articles for article (PubMed ID: 23702147)
1. The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor.
Mondal G; Barui S; Chaudhuri A
Biomaterials; 2013 Aug; 34(26):6249-60. PubMed ID: 23702147
[TBL] [Abstract][Full Text] [Related]
2. The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth.
Samanta S; Sistla R; Chaudhuri A
Biomaterials; 2010 Mar; 31(7):1787-97. PubMed ID: 19889452
[TBL] [Abstract][Full Text] [Related]
3. Cyclic RGD peptide-conjugated polyplex micelles as a targetable gene delivery system directed to cells possessing alphavbeta3 and alphavbeta5 integrins.
Oba M; Fukushima S; Kanayama N; Aoyagi K; Nishiyama N; Koyama H; Kataoka K
Bioconjug Chem; 2007; 18(5):1415-23. PubMed ID: 17595054
[TBL] [Abstract][Full Text] [Related]
4. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
[TBL] [Abstract][Full Text] [Related]
5. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor.
Hamano N; Negishi Y; Fujisawa A; Manandhar M; Sato H; Katagiri F; Nomizu M; Aramaki Y
Int J Pharm; 2012 May; 428(1-2):114-7. PubMed ID: 22421321
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference.
Majumder P; Bhunia S; Bhattacharyya J; Chaudhuri A
J Control Release; 2014 Apr; 180():100-8. PubMed ID: 24556418
[TBL] [Abstract][Full Text] [Related]
7. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
Nam JO; Jeong HW; Lee BH; Park RW; Kim IS
Cancer Res; 2005 May; 65(10):4153-61. PubMed ID: 15899806
[TBL] [Abstract][Full Text] [Related]
8. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors.
Jin ZH; Josserand V; Foillard S; Boturyn D; Dumy P; Favrot MC; Coll JL
Mol Cancer; 2007 Jun; 6():41. PubMed ID: 17565663
[TBL] [Abstract][Full Text] [Related]
9. A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9.
Sun LC; Luo J; Mackey LV; Fuselier JA; Coy DH
Cancer Lett; 2007 Feb; 246(1-2):157-66. PubMed ID: 16644105
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Nanotargeted
Liu SY; Lo SN; Lee WC; Hsu WC; Lee TW; Chang CH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499267
[TBL] [Abstract][Full Text] [Related]
11. αvβ3-Integrin-targeting lanthanide complex: synthesis and evaluation as a tumor-homing luminescent probe.
Ito T; Inoue M; Akamatsu K; Kusaka E; Tanabe K; Nishimoto S
Bioorg Med Chem Lett; 2011 Jun; 21(12):3515-8. PubMed ID: 21600766
[TBL] [Abstract][Full Text] [Related]
12. Integrin alphaVbeta3 contains a receptor site for resveratrol.
Lin HY; Lansing L; Merillon JM; Davis FB; Tang HY; Shih A; Vitrac X; Krisa S; Keating T; Cao HJ; Bergh J; Quackenbush S; Davis PJ
FASEB J; 2006 Aug; 20(10):1742-4. PubMed ID: 16790523
[TBL] [Abstract][Full Text] [Related]
13. αVβ3 Integrin-Targeted Radionuclide Therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4.
Jin ZH; Furukawa T; Degardin M; Sugyo A; Tsuji AB; Yamasaki T; Kawamura K; Fujibayashi Y; Zhang MR; Boturyn D; Dumy P; Saga T
Mol Cancer Ther; 2016 Sep; 15(9):2076-85. PubMed ID: 27422811
[TBL] [Abstract][Full Text] [Related]
14. Chemokine receptor 7 promotes cell migration and adhesion in metastatic squamous cell carcinoma of the head and neck by activating integrin αvβ3.
Li P; Liu F; Sun L; Zhao Z; Ding X; Shang D; Xu Z; Sun C
Int J Mol Med; 2011 May; 27(5):679-87. PubMed ID: 21347514
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo evaluation of a paclitaxel conjugate with the divalent peptide E-[c(RGDfK)2] that targets integrin alpha v beta 3.
Ryppa C; Mann-Steinberg H; Biniossek ML; Satchi-Fainaro R; Kratz F
Int J Pharm; 2009 Feb; 368(1-2):89-97. PubMed ID: 18992308
[TBL] [Abstract][Full Text] [Related]
16. Functionalization of small rigid platforms with cyclic RGD peptides for targeting tumors overexpressing αvβ3-integrins.
Morlieras J; Dufort S; Sancey L; Truillet C; Mignot A; Rossetti F; Dentamaro M; Laurent S; Vander Elst L; Muller RN; Antoine R; Dugourd P; Roux S; Perriat P; Lux F; Coll JL; Tillement O
Bioconjug Chem; 2013 Sep; 24(9):1584-97. PubMed ID: 23978076
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenesis activities of novel peptide complexes: mitochondria-disruptive 9mer peptides conjugated with the integrin alpha V beta 3-homing cyclic RGD motif.
Iwasaki T; Yamakawa M; Asaoka A; Kawano T; Ishibashi J
Biosci Biotechnol Biochem; 2012; 76(11):2044-8. PubMed ID: 23132564
[TBL] [Abstract][Full Text] [Related]
18. Cyclic-RGDyC functionalized liposomes for dual-targeting of tumor vasculature and cancer cells in glioblastoma: An in vitro boron neutron capture therapy study.
Kang W; Svirskis D; Sarojini V; McGregor AL; Bevitt J; Wu Z
Oncotarget; 2017 May; 8(22):36614-36627. PubMed ID: 28402271
[TBL] [Abstract][Full Text] [Related]
19. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
Cai W; Chen X
Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
[TBL] [Abstract][Full Text] [Related]
20. Radioiodinated bicyclic RGD peptide for imaging integrin α
Kondo N; Wakamori K; Hirata M; Temma T
Biochem Biophys Res Commun; 2020 Jul; 528(1):168-173. PubMed ID: 32451087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
